The invention relates to novel bicyclic compounds as novel and useful industrial products. The invention also relates to the process for preparing them and to their use in pharmaceutical compositions for use in human or veterinary medicine, or alternatively in cosmetic compositions.

Compounds with activity of retinoid type (vitamin A and its derivatives) are widely described in the literature as having activity in cell proliferation and differentiation processes. These properties give this class of compounds high potential in the treatment or prevention of numerous pathologies, and more particularly in dermatology and cancer. Many biological effects of retinoids are mediated by modulating the nuclear retinoic acid receptors (RAR).

The RAR receptors activate transcription by binding to DNA sequence elements, known as RAR response elements (RARE), in the form of a heterodimer with the retinoid X receptors (known as RXRs).

Three subtypes of human RARs have been identified and described: RARa, RARß and RARy.

The prior art contains a large number of chemical compounds with inhibitory activity on receptors of RAR type. Among the prior art documents that may be mentioned more particularly are patent EP 0 986 537 which describes heteroethynylenated compounds, patent US 6 103 762 which describes

biaromatic compounds whose aromatic nuclei are linked via a divalent propynylene or allenylene radical, patent US 6 150 413 which describes triaromatic compounds, patent US 5 723 499 which describes polycyclic aromatic compounds, and patent US 6 214 878 which describes stilbene compounds. Patent US 6 218 128. describes a family of bicyclic or tricyclic molecules.

The Applicant has invented novel bicyclic compounds that are inhibitors of the retinoic acid receptors.

Thus, the present invention relates to bicyclic compounds corresponding to the following general formula:

in which: Ri represents a radical of formulae (a) to (c) below :

R7 and R8 having the meanings given below, each of the radicals R2 and R3, which may be identical or different, represent a hydrogen atom or an alkyl radical containing from 1 to 6 carbon atoms, - X represents an Se atom,-CHOH,-CH2 or-C=0, -Q represents an oxygen atom, a sulphur atom, CH2, -NH or -NR9, Rg having the meanings given below, - R4 and Rs, which may be identical or different, represent a hydrogen atom, an alkyl radical containing from 1 to 6 carbon atoms, or together form an oxo radical, -R6 represents a phenyl radical, a naphthyl radical or a heterocyclic radical, R6 being optionally substituted with one or more radicals chosen from an alkyl containing from 1 to 6 carbon atoms, an-ORlo radical, a halogen atom,-CF3,-NH2 and a nitrogen atom mono-or disubstituted with an alkyl radical containing from 1 to 6 carbon atoms, Rlo having the meanings given below, - R7 represents a radical-CORll, R11 having the meanings given below, Re represents a radical:

R12, R13 and R14 having the meanings given below, - R9 represents an alkyl radical containing from 1 to 6 carbon atoms, - R10 represents a hydrogen atom or an alkyl radical containing from 1 to 6 carbon atoms, -Rll represents a radical-OR15 or a radical-NRlSRls, Ris and Rig having the meanings given below, - R12 and R13, which may be identical or different, represent a hydrogen atom, a halogen atom, an alkyl radical containing from 1 to 6 carbon atoms or a radical-OR17, Ri7 having the meanings given below, Ri4 represents a radical-COR18, R18 having the meanings given below, Ri5, Rig and R17, which may be identical or different, represent a hydrogen atom or an alkyl radical containing from 1 to 6 carbon atoms, Rig represents a radical-OR19, or a radical -NR19R20, Rl9 and R2o having the meanings given below, Rig represents a hydrogen atom or an alkyl radical containing from 1 to 6 carbon atoms, - R20 represents a hydrogen atom, an alkyl radical containing from 1 to 6 carbon atoms, or-OH, and the optical isomers, the salts obtained with a pharmaceutically acceptable salt or base, and also the mixtures of the said compounds of formula (I).

When the compounds according to the invention are in the form of a salt, it is preferably an alkali metal or alkaline-earth metal salt, or alternatively a zinc salt, or an organic amine salt.

According to the present invention: The expression"alkyl radical containing from 1 to 6 carbon atoms"preferably means the methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, or hexyl radicals.

The term"halogen atom"preferably means a fluorine, chlorine, or bromine atom.

The term"heterocycle"means a carbon-based ring of 5 to 8 carbon atoms interrupted with 1 or 2 hetero atoms chosen from sulphur, nitrogen, oxygen and selenium, and preferably a pyridine, pyrimidine or thiophene radical.

Among the compounds corresponding to the general formula (I) above that may be mentioned are the following, alone or as a mixture: 4- [4- (3-fluorobenzyloxy)-5, 5,8, 8-tetramethyl-5,6, 7,8- tetrahydro-2-naphthylselanylethynyl] benzoic acid 4- [5, 5,8, 8-tetramethyl-4- (4-methylbenzyloxy)-5, 6,7, 8- tetrahydro-2-naphthylselanylethynyl] benzoic acid 4- [4- (4-tert-butylbenzyloxy)-5, 5,8, 8-tetramethyl- 5,6, 7, 8,-tetrahydro-2-naphthylselanylethynyl] benzoic acid

4- [4- (3, 4-difluorobenzyloxy) -5,5, 8,8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthylselanylethynyl] benzoic acid 4- [4- (2, 4-difluorobenzyloxy) -5,5, 8,8-tetramethyl- 5,6, 7,8-tetrahydro-2-naphthylselanylethynyl] benzoic acid 4- [5, 5,8, 8-tetramethyl-4- (4-trifluoromethylbenzyloxy)- 5,6, 7, 8-tetrahydro-2-naphthylselanylethynyl] benzoic acid 4- [5, 5,8, 8-tetramethyl-4- (2-naphthylmethoxy)-5, 6,7, 8- tetrahydro-2-naphthylselanylethynyl] benzoic acid 4- [4- (4-chlorobenzyloxy)-5, 5, 8, 8-tetramethyl-5, 6,7, 8- tetrahydro-2-naphthylselanylethynyl] benzoic acid 4- [4- (4-bromobenzyloxy)-5, 5,8, 8-tetramethyl-5,6, 7,8- tetrahydro-2-naphthylselanylethynyl] benzoic acid 4- [5, 5,8, 8-tetramethyl-4- (3-methylbenzyloxy)-5, 6,7, 8- tetrahydro-2-naphthylselanylethynyl] benzoic acid 4- [4- (4-fluorobenzyloxy)-5, 5,8, 8-tetramethyl-5,6, 7,8- tetrahydro-2-naphthylselanylethynyl] benzoic acid 4- {3-hydroxy-3- [5, 5,8, 8-tetramethyl-4- (4- trifluoromethylbenzyloxy) -5,6, 7,8-tetrahydro-2- naphthyl] prop-l-ynyl} benzoic acid 4- {3-hydroxy-3- [5, 5,8, 8-tetramethyl-4- (4-tert- butylbenzyloxy)-5, 6,7, 8-tetrahydro-2-naphthyl] prop-1- ynyl} benzoic acid 4- {3-hydroxy-3- [5, 5,8, 8-tetramethyl-4- (4- methylbenzyloxy) -5,6, 7, 8-tetrahydro-2-naphthyl] prop-1-

ynyl} benzoic acid 4- {3- [4- (4-tert-butylbenzyloxy)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1- ynyl} benzoic acid 4- { (E)-3- [4- (4-fluorobenzyloxy)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-oxopropenyl} benzoic acid 6- {l- [4- (4-fluorobenzyloxy)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]methanoyl}naphthalene-2- carboxylic acid 6- {l- [4- (4-fluorobenzyloxy)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-1-hydroxymethyl}- naphthalene-2-carboxylic acid 4- {3- [4- (4-fluorobenzylamino)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxypropenyl}- benzoic acid 4- (3- {4- [ (4-fluorobenzyl) methylamino]-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3- oxopropenyl) benzoic acid 4- {3- [4- (4-fluorobenzylamino)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1- ynyl} benzoic acid 4- {3- [4- (4-fluorobenzylamino)-5, 5,8, 8-tetramethyl- 5, 6,7, 8-tetrahydro-2-naphthyl] -3-oxopropenyl} benzoic acid 4- (3- {4- [ (4-fluorobenzyl) methylamino]-5, 5, 8,8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3-

hydroxypropenyl) benzoic acid 4- (3- (4- [ (4-fluorobenzyl) methylamino] -5,5, 8,8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3- hydroxyprop-l-ynyl) benzoic acid 4- {3- [4- (4-fluorobenzylsulphanyl)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3- hydroxypropenyl} benzoic acid 4- {3- [4- (4-fluorobenzylsulphanyl)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-oxopropenyl} benzoic acid 4- {3- [4- (4-fluorobenzylsulphanyl)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1- ynyl} benzoic acid 4- {3- [4- (4-fluorobenzylamino)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxypropenyl}-2- hydroxybenzoic acid 4- (3- {4- [ (4-fluorobenzyl) methylamino] -tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl} oxopropenyl) -2- hydroxybenzoic acid 4- {3- [4- (4-fluorobenzylamino)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1-ynyl}-2- hydroxybenzoic acid 4- {3- [4- (4-fluorobenzylamino)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-oxopropenyl}-2- hydroxybenzoic acid 4- (3- {4- [ (4-fluorobenzyl) methylamino]-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3-

hydroxypropenyl) -2-hydroxybenzoic acid 4- (3- {4- [ (4-fluorobenzyl) methylamino] -5,5, 8,8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3- hydroxyprop-l-ynyl)-2-hydroxybenzoic acid 4- {3- [4- (4-fluorobenzylsulphanyl)-5, 5,8, 8-tetramethyl- 5,6, 7,8-tetrahydro-2-naphthyl]-3-hydroxypropenyl}-2- hydroxybenzoic acid 4- {3- [4- (4-fluorobenzylsulphanyl)-5, 5,8, 8-tetramethyl- 5, 6, 7,8-tetrahydro-2-naphthyl]-3-oxopropenyl}-2- hydroxybenzoic acid 4- {3- [4- (4-fluorobenzylsulphanyl)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1-ynyl}-2- hydroxybenzoic acid 4- {3- [4- (4-fluorobenzyloxy)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxypropenyl}-2- hydroxybenzoic acid 4- {3- (4- (4-fluorobenzyloxy)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-oxopropenyl}-2- hydroxybenzoic acid 4- {3- [4- (4-fluorobenzyloxy)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1-ynyl}-2- hydroxybenzoic acid 4- {3- [4- (4-fluorobenzoylamido)-5, 5,8, 8-tetramethyl- 5, 6,7, 8-tetrahydro-2-naphthyl]-3-hydroxypropenyl}- benzoic acid 4- (3- {4- [ (4-fluoro) methylbenzoylamido]-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3-

oxopropenyl) benzoic acid 4- {3- [4- (4-fluorobenzoylamido)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1- ynyl} benzoic acid - (3- {4- [ (4-fluoro) methylbenzoylamido]-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl}-3- hydroxypropenyl) benzoic acid 4- {3- [4- (4-fluorobenzoylamido)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-oxopropenyl} benzoic acid 4- (3- {4- [ (4-fluoro) methylbenzoylamido]-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl} hydroxyprop- 1-ynyl) benzoic acid 4-(3-{4-[1-(4-fluorophenyl)-1-methylethoxy]-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3- hydroxypropenyl) benzoic acid 4-(3-{4-[1-(4-fluorophenyl)-1-methylethoxy]-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl}-3- oxopropenyl) benzoic acid 4- (3- {4- [l- (4-fluorophenyl)-l-methylethoxy]-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3- hydroxyprop-1-yny1) benzoic acid 4- {3- [4- (4-methylbenzylamino)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxypropenyl}- benzoic acid 4- (3- {4- [ (4-methylbenzyl) methylamino]-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl}-3-

oxopropenyl) benzoic acid 4- {3- [4- (4-methylbenzylamino)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1- ynyl} benzoic acid 4- {3- [4- (4-methylbenzylamino)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-oxopropenyl} benzoic acid 4- (3- {4- [ (4-methylbenzyl) methylamino]-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3- hydroxypropenyl) benzoic acid 4- (3- {4- [ (4-methylbenzyl) methylamino] -5,5, 8,8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3- hydroxyprop-l-ynyl) benzoic acid 4- {3- [4- (4-methylbenzylsulphanyl)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxypropenyl}- benzoic acid 4- {3- [4- (4-methylbenzylsulphanyl)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-oxopropenyl} benzoic acid 4- {3- [4- (4-methylbenzylsulphanyl)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1- ynyl} benzoic acid 4- {3- [4- (4-methylbenzylamino)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxypropenyl}-2- hydroxybenzoic acid 4- (3- {4- [ (4-methylbenzyl) methylamino]-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl}-3-

oxopropenyl)-2-hydroxybenzoic acid 4- {3- [4- (4-methylbenzylamino)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1-ynyl}-2- hydroxybenzoic acid 4- {3- [4- (4-methylbenzylamino)-5, 5,8, 8-tetramethyl- 5,6, 7,8-tetrahydro-2-naphthyl]-3-oxopropenyl}-2- hydroxybenzoic acid 4- (3- {4- [ (4-methylbenzyl) methylamino]-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl}-3- hydroxypropenyl) -2-hydroxybenzoic acid 4- (3- {4- [ (4-methylbenzyl) methylamino]-5, 5,8, 8- tetramethyl-5, 6, 7, 8-tetrahydro-2-naphthyl}-3- hydroxyprop-1-ynyl)-2-hydroxybenzoic acid 4- {3- [4- (4-methylbenzylsulphanyl)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxypropenyl}-2- hydroxybenzoic acid 4- {3- [4- (4-methylbenzylsulphanyl)-5, 5,8, 8-tetramethyl- 5,6, 7,8-tetrahydro-2-naphthyl]-3-oxopropenyl}-2- hydroxybenzoic acid 4- {3- [4- (4-methylbenzylsulphanyl)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1-ynyl}-2- hydroxybenzoic acid 4- {3- [4- (4-methylbenzyloxy)-5, 5,8, 8-tetramethyl- 5, 6,7, 8-tetrahydro-2-naphthyl]-3-hydroxypropenyl}-2- hydroxybenzoic acid 4- {3- [4- (4-methylbenzyloxy)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-oxopropenyl}-2-

hydroxybenzoic acid 4- 3- [4- (4-methylbenzyloxy)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1-ynyl}-2- hydroxybenzoic acid 4- [3- (4- { [l- (4-methylphenyl) methanoyl] amino}-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl)-3- hydroxypropenyl] benzoic acid 4-[3-(4-{[1-(4-methylphenyl)methanoyl]methylamino}- 5,5, 8, 8-tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl) -3- oxopropenyl] benzoic acid 4-[3-(4-{[1-(4-methylphenyl)methanoyl]amino}-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl)-3- hydroxyprop-l-ynyl] benzoic acid 4- [3- (4- { [l- (4-methylphenyl) methanoyllmethylamino)- 5,5, 8,8-tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl)-3- hydroxypropenyl] benzoic acid 4-[3-(4-{[1-(4-methylphenyl)methanoyl]amino}-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl)-3- oxopropenyl] benzoic acid 4- (3- (4- {1- (4-4-methylphenyl) methanoyl] methylamino}- 5,5, 8,8-tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl) -3- hydroxyprop-l-ynyl] benzoic acid 4- (3- {4- [1- (4-methylphenyl)-1-methylethoxy]-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3- hydroxypropenyl) benzoic acid 4- (3- {4- [1- (4-methylphenyl)-1-methylethoxy]-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl}-3-

oxopropenyl) benzoic acid 4- (3- {4- [l- (4-methylphenyl)-l-methylethoxy]-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3- hydroxyprop-l-ynyl) benzoic acid 4- {3- [4- (4-dimethylaminobenzylamino)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3- hydroxypropenyl} benzoic acid 4- (3- {4- [ (4-dimethylaminobenzyl) methylamino]-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3- oxopropenyl) benzoic acid 4- {3- [4- (4-dimethylaminobenzylamino)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3- hydroxyprop-l-ynyl} benzoic acid 4- {3- [4- (4-dimethylaminobenzylamino)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3- oxopropenyl} benzoic acid 4- (3- {4- [ (4-dimethylaminobenzyl) methylamino]-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3- hydroxypropenyl) benzoic acid 4- (3- {4- [ (4-dimethylaminobenzyl) methylamino]-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl}-3- hydroxyprop-1-ynyl) benzoic acid 4- {3- [4- (4-dimethylaminobenzylsulphanyl)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3- hydroxypropenyl} benzoic acid 4- {3- [4- (4-dimethylaminobenzylsulphanyl)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3-

oxopropenyl} benzoic acid 4- {3- [4- (4-dimethylaminobenzylsulphanyl)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3- hydroxyprop-l-ynyl} benzoic acid 4- {3- [4- (4-dimethylaminobenzylamino)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3- hydroxypropenyl} -2-hydroxybenzoic acid 4- (3- {4- [ (4-dimethylaminobenzyl) methylamino] -5,5, 8,8- tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl}-3- oxopropenyl) -2-hydroxybenzoic acid 4- {3- [4- (4-dimethylaminobenzylamino)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3- hydroxyprop-l-ynyl}-2-hydroxybenzoic acid 4- {3- [4- (4-dimethylaminobenzylamino)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3- oxopropenyl} -2-hydroxybenzoic acid 4- (3- {4- [ (4-dimethylaminobenzyl) methylamino] -5,5, 8,8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3- hydroxypropenyl) -2-hydroxybenzoic acid 4- (3- {4- [ (4-dimethylaminobenzyl) methylamino]-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3- hydroxyprop-l-ynyl)-2-hydroxybenzoic acid 4- {3- [4- (4-dimethylaminobenzylsulphanyl)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3- hydroxypropenyl}-2-hydroxybenzoic acid 4- {3- [4- (4-dimethylaminobenzylsulphanyl)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3-

oxopropenyl} -2-hydroxybenzoic acid 4-{3-[4-(4-dimethylaminobenzylsulphanyl)-5 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3- hydroxyprop-l-ynyl}-2-hydroxybenzoic acid 4- {3- [4- (4-dimethylaminobenzyloxy)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxypropenyl}-2- hydroxybenzoic acid 4- {3- [4- (4-dimethylaminobenzyloxy)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-oxopropenyl}-2- hydroxybenzoic acid 4- {3- [4- (4-dimethylaminobenzyloxy)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1-ynyl}-2- hydroxybenzoic acid 4-[3-(4-{[1-(4-dimethylaminophenyl)methanoyl]amino}- 5, 5,8, 8-tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl)-3- hydroxypropenyl] benzoic acid 4-[3-(4-{[1-(4-dimethylaminophenyl)methanoyl]- methylamino} -5,5, 8,8-tetramethyl-5, 6,7, 8-tetrahydro-2- naphthyl)-3-oxopropenyl] benzoic acid 4- [3- (4- { [l- (4-dimethylaminophenyl) methanoyl] amino}- 5,5, 8,8-tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl) -3- hydroxyprop-l-ynyl] benzoic acid 4- (3- (4- ( (l- (4-dimethylaminophenyl) methanoyl] methyl- amino}-5, 5,8, 8-tetramethyl-5,6, 7,8-tetrahydro-2- naphthyl)-3-hydroxypropenyl] benzoic acid 4-[3-(4-{[1-(4-dimethylaminophenyl)methanoyl]amino}- 5,5, 8,8-tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl) -3-

oxopropenyl] benzoic acid 4- [3- (4- ( [l- (4-dimethylaminophenyl) methanoyl] - methylamino}-5, 5,8, 8-tetramethyl-5, 6,7, 8-tetrahydro-2- naphthyl)-3-hydroxyprop-1-ynyl] benzoic acid 4- (3- {4- [l- (4-dimethylaminophenyl)-l-methylethoxy]- 5,5, 8,8-tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl}-3- hydroxypropenyl) benzoic acid 4- (3- {4- [1- (4-dimethylaminophenyl)-1-methylethoxy]- 5,5, 8,8-tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl}-3- oxopropenyl) benzoic acid 4- (3- {4- [l- (4-dimethylaminophenyl)-l-methylethoxy]- 5,5, 8,8-tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl}-3- hydroxyprop-l-ynyl) benzoic acid 4- (3- {4- [2- (4-fluorophenyl) ethyl]-5, 5,8, 8-tetramethyl- 5,6, 7,8-tetrahydro-2-naphthyl}-3-hydroxypropenyl)- benzoic acid 4- (3- {4- [2- (4-fluorophenyl) ethyl]-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl}-3-oxopropenyl) benzoic acid 4- (3- {4- [2- (4-fluorophenyl) ethyl]-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl}-3-hydroxyprop-1- ynyl) benzoic acid 4- (3- {4- [2- (4-fluorophenyl)-2-methylpropyl]-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3- hydroxypropenyl) benzoic acid 4- (3- (4.- [2- (4-fluorophenyl)-2-methylpropyl]-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3-

oxopropenyl) benzoic acid 4- (3- {4- [2- (4-fluorophenyl)-2-methylpropyl]-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3- hydroxyprop-l-ynyl) benzoic acid 4- (3- {4- [2- (4-methylphenyl) ethyl] -5,5, 8,8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl}-3-hydroxypropenyl)- benzoic acid 4- (3- {4- [2- (4-methylphenyl) ethyl]-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl}-3-oxopropenyl) benzoic acid 4- (3- {4- [2- (4-methylphenyl) ethyl]-5, 5,8, 8-tetramethyl-.

5,6, 7, 8-tetrahydro-2-naphthyl}-3-hydroxyprop-1- ynyl) benzoic acid 4- (3- (4- [2- (4-methylphenyl)-2-methylpropyl]-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl}-3- hydroxypropenyl) benzoic acid 4- (3- {4- [2- (4-methylphenyl)-2-methylpropyl]-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl}-3- oxopropenyl) benzoic acid 4- (3- {4- [2- (4-methylphenyl)-2-methylpropyl]-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl}-3- hydroxyprop-l-ynyl) benzoic acid 4- (3- {4- [2- (4-dimethylaminophenyl) ethyl] -5,5, 8,8- tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl} -3- hydroxypropenyl) benzoic acid 4- (3- {4- [2- (4-dimethylaminophenyl) ethyl]-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3-

oxopropenyl) benzoic acid 4- (3- {4- [2- (4-dimethylaminophenyl) ethyl]-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl}-3- hydroxyprop-1-ynyl) benzoic acid 4- (3- {4- [2- (4-dimethylaminophenyl)-2-methylpropyl]- 5,5, 8,8-tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl} -3- hydroxypropenyl) benzoic acid 4- (3- {4- [2- (4-dimethylaminophenyl)-2-methylpropyl]- 5,5, 8,8-tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl} -3- oxopropenyl) benzoic acid 4- (3- {4- [2- (4-dimethylaminophenyl)-2-methylpropyl]- 5,5, 8,8-tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl} -3- hydroxyprop-l-ynyl) benzoic acid 4-{3-[4-(4-fluorobenzyloxy)-5, 6,7, 8-tetrahydro-2- naphthyl]-3-hydroxypropenyl} benzoic acid 4- {3- [4- (4-fluorobenzyloxy)-8, 8-dimethyl-5,6, 7,8- tetrahydro-2-naphthyl]-3-hydroxypropenyl} benzOic acid 4- {3- [4- (4-fluorobenzyloxy)-5, 5-dimethyl-5,6, 7,8- tetrahydro-2-naphthyl]-3-hydroxypropenyl} benzoic acid 4- (3- (4- [ (4-fluorobenzyl) methylamino]-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3- hydroxyprop-l-ynyl) benzamide 4- (3- {4- [ (4-fluorobenzyl) methylamino]-5, 5,8, 8- tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl} -3- hydroxyprop-1-ynyl)-N-hydroxybenzamide N-ethyl-4- (3- {4- [ (4-fluorobenzyl) methylamino]-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3-

hydroxyprop-1-ynyl) benzamide 4- {3- [4- (4-fluorobenzyloxy)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1- ynyl} benzamide 4- {3- [4- (4-fluorobenzyloxy)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1-ynyl}-N- hydroxybenzamide N-ethyl-4- {3- [4- (4-fluorobenzyloxy)-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl]-3- hydroxyprop-1-ynyl} benzamide 4-{3-[4-(4-fluorobenzylamino)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1- ynyl} benzamide 4- {3- [4- (4-fluorobenzylamino)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1-ynyl}-N- hydroxybenzamide N-ethyl-4- {3- [4- (4-fluorobenzylamino)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3- hydroxyprop-l-ynyl} benzamide 4- {3- [4- (4-fluorobenzylsulphanyl)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1- ynyl} benzamide 4- {3- (4- (4-fluorobenzylsulphanyl)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1-ynyl}-N- hydroxybenzamide N-ethyl-4- {3- [4- (4-fluorobenzylsulphanyl)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3-

hydroxyprop-l-ynyl} benzamide N-ethyl-4- (3- {4- [ (4-fluorobenzyl) methylamino]-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3- hydroxyprop-1-ynyl)-N-methylbenzamide N-ethyl-4- (3- [4- (4-fluorobenzyloxy)-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl]-3- hydroxyprop-1-ynyl}-N-methylbenzamide N-ethyl-4- {3- [4- (4-fluorobenzylamino)-5, 5,8, 8- tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl]-3- hydroxyprop-l-ynyl}-N-methylbenzamide N-ethyl-4- {3- [4- (4-fluorobenzylsulphanyl)-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl]-3- hydroxyprop-l-ynyl}-N-methylbenzamide 4- (3- {4- [ (4-methylbenzyl) methylamino]-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl}-3- hydroxyprop-1-ynyl) benzamide 4- (3- {4- [ (4-methylbenzyl) methylamino]-5, 5,8, 8- tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl} -3- hydroxyprop-l-ynyl)-N-hydroxybenzamide N-ethyl-4- (3- (4- [ (4-methylbenzyl) methylamino]-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3- hydroxyprop-l-ynyl) benzamide 4- {3- [4- (4-methylbenzyloxy)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1- ynyl} benzamide 4- {3- [4- (4-methylbenzyloxy)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1-ynyl}-N-

hydroxybenzamide N-ethyl-4- {3- [4- (4-methylbenzyloxy)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3- hydroxyprop-1-ynyl} benzamide 4- {3- [4- (4-methylbenzylamino)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1- ynyl} benzamide 4- {3- [4- (4-methylbenzylamino)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1-ynyl}-N- hydroxybenzamide N-ethyl-4- {3- [4- (4-methylbenzylamino)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3- hydroxyprop-l-ynyl} benzamide 4- {3- [4- (4-methylbenzylsulphanyl)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1- ynyl} benzamide 4- (3- [4- (4-methylbenzylsulphanyl)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1-ynyl}-N- hydroxybenzamide N-ethyl-4- {3- [4- (4-methylbenzylsulphanyl)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3- hydroxyprop-1-ynyl} benzamide N-ethyl-4- (3- {4- [ (4-methylbenzyl) methylamino]-5, 5,8, 8- tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl}-3- hydroxyprop-1-ynyl)-N-methylbenzamide N-ethyl-4- {3- [4- (4-methylbenzyloxy)-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl]-3-

hydroxyprop-1-ynyl}-N-methylbenzamide N-ethyl-4- {3- [4- (4-methylbenzylamino)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3- hydroxyprop-1-ynyl}-N-methylbenzamide N-ethyl-4- {3- [4- (4-methylbenzylsulphanyl)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3- hydroxyprop-1-ynyl}-N-methylbenzamide 4- (3- {4- [ (4-dimethylaminobenzyl) methylamino]-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3- hydroxyprop-l-ynyl] benzamide 4- (3- {4- [ (4-dimethylaminobenzyl) methylamino] -5,5, 8,8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl}-3- <BR> <BR> hydroxyprop-l-ynyl)-N-hydroxybenzamide<BR> <BR> N-ethyl-4- (3- {4- [ (4-dimethylaminobenzyl) methylamino]- 5,5, 8,8-tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl} -3- hydroxyprop-1-ynyl) benzamide 4- {3- [4- (4-dimethylaminobenzyloxy)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1- ynyl} benzamide 4- {3- [4- (4-dimethylaminobenzyloxy)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxyprop-1-ynyl}-N- hydroxybenzamide N-ethyl-4- {3- [4- (4-dimethylaminobenzyloxy)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3- hydroxyprop-l-ynyl} benzamide 4- {3- [4- (4-dimethylaminobenzylamino)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3-

hydroxyprop-1-ynyl} benzamide 4- {3- [4- (4-dimethylaminobenzylamino)-5, 5,8, 8- tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl] -3- hydroxyprop-1-ynyl}-N-hydroxybenzamide N-ethyl-4- {3- [4- (4-dimethylaminobenzylamino)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3- hydroxyprop-l-ynyl) benzamide 4- {3- [4- (4-dimethylaminobenzylsulphanyl)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3- hydroxyprop-1-ynyl} benzamide 4- {3- [4- (4-dimethylaminobenzylsulphanyl)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3- hydroxyprop-1-ynyl}-N-hydroxybenzamide N-ethyl-4- {3- [4- (4-dimethylaminobenzylsulphanyl)- 5,5, 8,8-tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl]-3- hydroxyprop-l-ynyl} benzamide N-ethyl-4- (3- {4- [ (4-dimethylaminobenzyl) methylamino]- 5,5, 8,8-tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl]-3- hydroxyprop-1-ynyl)-N-methylbenzamide N-ethyl-4- {3- [4- (4-dimethylaminobenzyloxy)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3- hydroxyprop-l-ynyl}-N-methylbenzamide N-ethyl-4- {3- [4- (4-dimethylaminobenzylamino)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3- hydroxyprop-l-ynyl}-N-methylbenzamide or N-ethyl-4- {3- [4- (4-dimethylaminobenzylsulphanyl)- 5,5, 8,8-tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl]-3-

hydroxyprop-l-ynyl}-N-methylbenzamide.

According to the present invention, the compounds of formula (I) that are more particularly preferred are those for which: Ri represents (b), Q represents an oxygen atom, and Rg represents (i).

The subject of the present invention is also the processes for preparing the compounds of formula (I), in particular according to the reactions schemes given in Figure 1.

A general description of the preparation of the compounds of general formulae 6 to 12 is given below.

Intermediate 2 may be formed from 3-bromophenol, via a Friedel-Crafts reaction in the presence of aluminium chloride and a corresponding partner, for instance 2,5-dichloro-2, 5-dimethylhexane.

The compounds of general structure 3 may be obtained by converting the bromide of 2 into an acid or an aldehyde after lithiation with butyllithium, or, in the case where R = SH or SeH, the compounds of general structure 3 may be obtained by lithiation of 3 and attack of the anion formed on the native sulphur or selenium. These compounds may then be converted into the corresponding disulphides or diselenides by spontaneous oxidation in

non-gassed ethanol, after which the compounds 4 may be prepared by forming the sulphide or selenide bromide by the action of bromine on the disulphide or diselenide function, followed by addition of a true alkyne in the presence of copper iodide in dimethylformamide, for example. After 0-alkylation of the phenol function of the compounds of structure 4, for example by nucleophilic substitution with a halogenated compound in the presence of sodium hydride, the compounds of structure 6 are obtained after saponification of the ester function, for example by reaction with sodium hydroxide.

In the case where Q = O, the compounds 5 may be obtained after 0-alkylation of the phenol function of the compounds of structure 3, for example by nucleophilic substitution with a halogenated'compound in the presence of sodium hydride. In the case where Q = S or N-R, the phenol may first be converted into trifluoromethanesulphonyl by reaction with trifluoromethanesulphonic anhydride, and. this intermediate is then coupled with a thiolate or an amine, respectively, in the presence of transition metal complexes, for instance bis-pyridyldichloronickel or dichlorobisphosphinoferrocenylpalladium, respectively. In the case where Q = CRllRl2 or C=O, the compound obtained after reaction of 3 with trifluoromethanesulphonic anhydride may be coupled

according to the Stille procedure with, for example, organotin derivatives, with or without pressure of carbon monoxide, respectively.

The compounds 3 for which R = COOR'may be converted into acids by saponification, and then into methyl ketones by reaction with methyl lithium: the compounds 5 in which R = COMe will thus be obtained.

When the compounds of'general structure 5 are obtained, compounds 7-12 are obtained in the following manner: The compounds 7 may be obtained by forming the acids corresponding to the esters 5, followed by conversion of these acids into the acid chlorides thereof, for example by reaction with thionyl chloride.

These acid chlorides may then be coupled with organometallic derivatives of naphthylzinc type, or with naphthoic boronic acids, in the presence of catalysts based on transition metals, for example tetrakis (triphenylphosphino) palladium. The precursors of the compounds of general structure 7 are generally obtained in the form of esters: the acids of structure 7 may be obtained by saponification, for example by reaction with sodium hydroxide.

The compounds 8 may be prepared by forming a chalcone bond by reacting the methyl ketone of 5 with a corresponding aromatic aldehyde in the presence of potassium hydroxide.

The compounds of general structure 9 may be prepared from the aldehyde 5 by creating a propargyl alcohol function by addition of a propargyl anion, for example by reaction with ethynyl magnesium bromide, followed by a Sonogashira coupling with an aromatic halide, for instance 4-iodobenzoic acid in the presence of copper salts and a catalyst based on a transition metal complex, for instance tetrakis (triphenylphosphino) palladium.

The compounds of general structure 10 may be obtained from the compounds of structure 7, for example after reduction or alkylation of the carbonyl function (R, R'= OH, H or alkyl, respectively), or alternatively by reduction followed by a dehydroxylation (R, R'= H, H), or acetalization of the carbonyl function (R, R' OR,. OR), or formation of an oxime on the carbonyl function of 7 by reaction with a corresponding hydroxyl or alkoxylamine.

The compounds of general structure 11 may be obtained from the compounds of structure 8, for example after reduction or alkylation of the carbonyl function (R, R' = OH, H or alkyl, respectively), for example by reaction with sodium borohydride or an alkymagnesium halide.

The compounds of general structure 12 may be prepared from the compounds of structure 9, by oxidation of the benzyl alcohol to a ketone (R, R'

C=O), for example after reaction with manganese oxide, or oxidation followed by the formation of an oxime on the carbonyl function of 9 by reaction with a corresponding hydroxyl or alkoxylamine (R, R' = C=N-OR), or dehydroxylation of the benzyl alcohol function (R, R' = H, H), for example by reaction with triethylsilane in the presence of boron trifluoride, or by oxidation and formation of an acetal (R, R' = OR, OR), or by oxidation and alkylation of the carbonyl function (R, R' = alkyl, OH), for example by addition of an alkylmagnesium halide, or by 0-alkylation of the alcohol function of 9 (R, R' = OR, H).

The compounds according to the invention have inhibitory properties of RAR-type receptors. This RAR- receptor inhibitory activity is measured in a test of transactivation by means of the dissociation constant Kdapp (apparent) and the IC50 (concentration that inhibits 50% of the reference agonist activity).

According to the invention, the expression "inhibitor of RAR-type receptors"means any compound which, for at least one of the RAR subtypes, has a dissociation constant Kdapp of less than or equal to 1 jum, and an ICso value < 100 nM, in a transactivation test as described in Example 19.

The preferred compounds of the present invention have, for at least one of the RAR subtypes, a dissociation constant Kdapp of less than or equal to

500 nM and advantageously less than or equal to 100 Nm, and an ICso < 25 nM.

A subject of the present invention is also the compounds of formula (I) as described above, as medicinal products.

The compounds according to the invention are particularly suitable in the following fields of treatment : 1) for treating dermatological complaints associated with a keratinization disorder relating to cell differentiation and proliferation, especially for treating common acne, comedones, polymorphs, acne rosacea, nodulocystic acne, acne conglobata, senile acne, and secondary acnes such as solar acne, medication-related acne or occupational acne; 2) for treating other types of keratinization disorders, especially ichthyosis, ichthyosiform conditions, Darier's disease, palmoplantar keratoderma, leukoplakia and leukoplakiform conditions, and cutaneous or mucous (buccal) lichen; 3) for treating other dermatological complaints with an inflammatory immunoallergic component, with or without cell proliferation disorder, and especially all forms of psoriasis, whether cutaneous, mucous or ungual, and even psoriatic rheumatism, or cutaneous atopy, such as eczema, or respiratory atopy, or alternatively gingival hypertrophy;

4) for treating all dermal or epidermal proliferations, whether benign or malignant, and whether of viral origin or otherwise, such as common warts, flat warts and verruciform epidermodysplasia, oral or florid papillomatoses, T lymphoma, and proliferations that may be induced by ultraviolet radiation, especially in the case of basocellular and spinocellular epithelioma, and also any cutaneous precancerous lesion such as keratoacanthomas; 5) for treating other dermatological disorders such as immune dermatoses, such as lupus erythematosus, immune bullous diseases and collagen diseases, such as scleroderma; 6) in the treatment of dermatological or general complaints with an immunological component; 7) for treating certain ophthalmological disorders, especially corneopathies, 8) for preventing or curing the stigmata of epidermal and/or dermal atrophy induced by local or systemic corticosteroids, or any other form of cutaneous atropy, 9) in the treatment of any cutaneous or general complaint of viral origin, 10) in the treatment of skin disorders caused by exposure to W radiation, and also for repairing or combating ageing of the skin, whether photoinduced or chronological ageing, or for reducing pigmentations and actinic keratosis, or any pathology associated with

chronological or actinic ageing, such as xerosis; 11) for combating sebaceous function disorders, such as the hyperseborrhoea of acne or simple seborrhoea; 12) for preventing or treating cicatrization disorders, or for preventing or repairing stretch marks, or alternatively for promoting cicatrization; 13) in the treatment of pigmentation disorders, such as hyperpigmentation, melasma, hypopigmentation or vitiligo; 14) in the treatment of lipid metabolism complaints, such as obesity, hyperlipidaemia, or non-insulin- dependent diabetes; 15) in the treatment of inflammatory complaints such as arthritis; ì6) in the treatment or prevention of cancerous or precancerous conditions; 17) in the prevention or treatment of alopecia of various origins, especially alopecia caused by chemotherapy or radiation; 18) in the treatment of disorders of the immune system, such as asthma, type I sugar diabetes, multiple sclerosis or other selective dysfunctions of the immune system; and 19) in the treatment of complaints of the cardiovascular system, such as arteriosclerosis or hypertension.

A subject of the present invention is also a

pharmaceutical composition comprising, in a physiologically acceptable medium, at least one compound of formula (I) as defined above.

A subject of the present invention is also a novel medicinal composition intended especially for treating the abovementioned complaints, which is characterized in that it comprises, in a pharmaceutically acceptable support that is compatible with the mode of administration selected for this composition, at least one compound of formula (I), an optical isomer thereof or a salt thereof.

The composition according to the invention may be administered enterally, parenterally, topically or ocularly. The pharmaceutical composition is preferably packaged in a form that is suitable for topical application.

Via the enteral route, the composition may be in the form of tablets, gel capsules, dragees, syrups, suspensions, solutions, powders, granules, emulsions, suspensions of microspheres or nanospheres or lipid or polymer vesicles allowing a controlled release. Via the parenteral route, the composition may be in the form of solutions or suspensions for infusion or for injection.

The compounds according to the invention are generally administered at a daily dose of about 0.01 mg/kg to 100 mg/kg of body weight, in 1 to 3 dosage intakes.

The compounds are used systemically, at a concentration generally of between 0. 001% and 10% by weight and preferably between 0. 01% and 1% by weight relative to the weight of the composition.

Via the topical route, the pharmaceutical composition according to the invention is more particularly intended for treating the skin and mucous membranes and may be in liquid, pasty or solid form, and more particularly in the form of ointments, creams, milks, pomades, powders, impregnated pads, syndets, solutions, gels, sprays, mousses, suspensions, sticks, shampoos or washing bases. It may also be in the form of suspensions of microspheres or nanospheres or of lipid or polymer vesicles or gelled or polymer patches allowing a controlled release.

The compounds are used topically at a concentration generally of between 0. 001% and 10% by weight and preferably between 0. 01% and 1% by weight, relative to the total weight of the composition.

The compounds of formula (I) according to the invention also find an application in cosmetics, in particular in body and hair hygiene and especially for treating acne-prone skin, for promoting regrowth of the hair or for limiting hair loss, for combating the greasy appearance of the skin or the hair, in protection against the harmful aspects of sunlight or in the treatment of physiologically dry skin, and for

preventing and/or combating photoinduced or chronological ageing.

A subject of the invention is thus also a composition comprising, in a cosmetically acceptable support, at least one of the compounds of formula (I).

A subject of the invention is also the cosmetic use of a composition comprising at least one compound of formula (I) for preventing and/or treating the signs of ageing and/or dry skin.

A subject of the invention is also the cosmetic use of a composition comprising at least one compound of formula (I) for body or hair hygiene.

The cosmetic composition according to the invention containing, in a cosmetically acceptable support, at least one compound of formula (I) or an optical or geometrical isomer thereof or a salt thereof, may be especially in the form of a cream, a milk, a gel, suspensions of microspheres or nanospheres or lipid or polymer vesicles, impregnated pads, solutions, sprays, mousses, sticks, soaps, shampoos or washing bases.

The concentration of compound of formula (I) in the cosmetic composition is preferably between 0. 001% and 3% by weight relative to the total weight of the composition.

The pharmaceutical and cosmetic compositions as described above may also contain inert additives, or

even pharmacodynamically active additives as regards the pharmaceutical compositions, or combinations of these additives, and especially: - wetting agents; - flavour enhancers; - preserving agents such as para-hydroxybenzoic acid esters; - stabilizers ; - moisture regulators ; - pH regulators; - osmotic pressure modifiers; - emulsifiers ; - UV-A and UV-B screening agents; - antioxidants such as a-tocopherol, butylhydroxyanisole, butylhydroxytoluene, superoxide dismutase, ubiquinol or certain metal-chelating agents; - depigmenting agents such as hydroquinone, azelaic acid, caffeic acid or kojic acid; - emollients ; - moisturizers, for instance glycerol, PEG 400, thiamorpholinone and its derivatives or urea; - antiseborrhoeic or antiacne agents, such as S-carboxymethylcysteine, S-benzylcysteamine, salts thereof or derivatives thereof, or benzoyl peroxide; - antibiotics, for instance erythromycin and its

esters, neomycin, clindamycin and its esters, and tetracyclines; antifungal agents such as ketoconazole or poly-4,5- methylene-3-isothiazolidones; agents for promoting regrowth of the hair, for instance Minoxidil (2,4-diamino-6- piperidinopyrimidine 3-oxide) and its derivatives, Diazoxide (7-chloro 3-methyl-1, 2,4-benzothiadiazine 1, 1-dioxide) and Phenytoin (5,4-diphenylimidazolidine-2, 4-dione); non-steroidal anti-inflammatory agents; carotenoids and especially ß-carotene ; anti-psoriatic agents such as anthralin and its derivatives; eicosa-5,8, 11, 14-tetraynoic acid and eicosa-5,8, 11- triynoic acid, and esters and amides thereof; retinoids, i. e., natural or synthetic RXR receptor ligands; corticosteroids or oestrogens; a-hydroxy acids and a-keto acids or derivatives thereof, such as lactic acid, malic acid, citric acid, glycolic acid, mandelic acid, tartaric acid, glyceric acid or ascorbic acid, and also salts, amides or esters thereof, or a-hydroxy acids or derivatives thereof, such as salicylic acid and its salts, amides or esters; ion-channel blockers such as potassium-channel

blockers; - or alternatively, more particularly for pharmaceutical compositions, in combination with medicinal products known to interfere with the immune system (for example cyclosporin, FK 506, glucocorticoids, monoclonal antibodies, cytokines or growth factors, etc.).

Needless to say, a person skilled in the art will take care to select the optional compound (s) to be added to these compositions such that the advantageous properties intrinsically attached to the present invention are not, or are not substantially, adversely affected by the envisaged addition.

Several examples of the production of active compounds of formula (I) according to the invention, biological activity results and also various concrete formulations based on such compounds, will now be given, for illustrative purposes and with no limiting nature.

EXAMPLE 1: 4- [4- (3-fluorobenzyloxy)-5, 5,8, 8- tetramethyl-5, 6,7, 8-tetrahydro-2- naphthylselanylethynyl] benzoic acid a. 3-Bromo-5,5, 8, 8-tetramethyl-5, 6, 7, 8-tetrahydro-1- naphthyl 60 g (347 mmol) of 3-bromophenol are dissolved in 600 mL of dichloromethane. This solution is added to a solution of 46 g (347 mmol) of aluminium

chloride in 200 mL of dichloromethane. 127 g (694 mmol) of 2,5-dichloro-2, 5-dimethylhexane are added in 10 g portions every 40 minutes. The medium is then stirred for 10 hours, after which it is poured onto ice and extracted with dichloromethane. The residue obtained is dissolved in ethyl ether and this organic phase is then washed with 1 N sodium hydroxide solution and then with water. The residue obtained is purified by chromatography (eluent: heptane and then 1/1 heptane/dichloromethane). A thick oil is obtained (67 g; yield = 68%). b. 7-Bromo-5-ethoxymethoxy-1, 1, 4, 4-tetramethyl- 1, 2,3, 4-tetrahydronaphthalene 42 g (148 mmol) of 3-bromo-5,5, 8,8- tetramethyl-5,6, 7, 8-tetrahydro-1-naphthyl are dissolved in 400 mL of anhydrous DMF. 7.2 g (178 mmol) of 60% sodium hydride are added portionwise and the reaction medium is stirred for one hour. 16.5 mL (178 mmol) of ethoxymethyl chloride are added dropwise and the medium is stirred at room temperature for 2 hours and then hydrolyzed and extracted with ethyl ether. The organic phase is washed with 1 N sodium hydroxide solution and then three times with water. The residue obtained is purified by chromatography (eluent: heptane). A yellow oil is obtained (m = 45.7 g; yield = 95%). c. Bis (4-ethoxymethoxy-5, 5,8, 8-tetramethyl-5, 6,7, 8- tetrahydro-2-naphthalene) diselenide

10 g (30.8 mmol) of 7-bromo-5-ethoxymethoxy- 1, 1, 4, 4-tetramethyl-1, 2,3, 4-tetrahydronaphthalene are dissolved in 200 mL of anhydrous THF. The medium is cooled to-78°C and 20 mL (34 mmol) of 1. 7 M tert- butyllithium solution are added dropwise. The medium is stirred for one hour and then added via a cannula to a suspension of 2.68 g (34 mmol) of selenium in 100 mL [lacuna] at-78°C. The reaction medium is warmed to room temperature and then stirred for 2 hours and treated with saturated ammonium chloride solution. The residue obtained after extraction is dissolved in 100 mL of ethanol, and 100 mg of sodium hydroxide are added. The reaction medium is stirred for 12 hours and then concentrated. The desired product is obtained after purification by chromatography (eluent: 95/5 heptane/ethyl acetate) (m = 10 g, yield = 95%). d. Methyl 4- (4-ethoxymethoxy-5, 5, 8, 8-tetramethyl- 5, 6, 7, 8-tetrahydro-2-naphthylselanylethynyl) benzoate 10 g (14.7 mmol) of bis (4-ethoxymethoxy-5,5, 8,8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthalene) diselenide are dissolved in 200 mL of anhydrous THF and the medium is cooled to-78°C. 13.9 mL (13.9 mmol) of a 1 N solution of bromine in THF are added slowly. The medium is stirred for one hour and 300 mL of DMF are then added, followed by addition of 4.65 g (26.4 mmol) of methyl 4-ethynylbenzoate and 16.8 g of copper iodide. The reaction medium is warmed to room

temperature and stirred for 48 hours, and is then hydrolyzed and extracted with ethyl acetate. A thick oil is obtained after purification by chromatography (eluent: 9/1 heptane/ethyl acetate) (m = 9.8 g; yield = 74%). e. Methyl 4- (4-hydroxy-5, 5, 8, 8-tetramethyl-5, 6, 7, 8- tetrahydro-2-naphthylselanylethynyl) benzoate 9 g (18 mmol) of methyl 4- (4-ethoxymethoxy- 5,5, 8,8-tetramethyl-5, 6,7, 8-tetrahydro-2- naphthylselanyethynyl) benzoate are dissolved in 100 mL of methanol, and 2 mL of sulphuric acid are added. The medium is refluxed for 2 hours and is then hydrolyzed and extracted with dichloromethane. The residue is purified by chromatography (eluent: dichloromethane). A yellow solid is obtained (m = 7.2 g; yield = 90% ; m. p.

= 139°C). f. Methyl 4- [4- (3-fluorobenzyloxy)-5, 5,8, 8- tetramethyl-5, 6, 7, 8-tetrahydro-2- naphthylselanylethynyl] benzoate 600 mg (1.35 mmol) of methyl 4- (4-hydroxy- 5,5, 8,8-tetramethyl-5, 6,7, 8-tetrahydro-2- naphthylselanylethynyl) benzoate are dissolved in 40 mL of 2-butanone. 182 Al (1.48 mmol) of 3-fluorobenzyl bromide are added, followed by addition of 250 mg (1. 8 mmol) of potassium carbonate. The reaction medium is refluxed for 10 ten hours and then cooled and filtered.

After washing the solid residue obtained with heptane,

a white solid is obtained (m = 683 mg; yield = 92% ; m. p. = 132°C). g. 4- (4- (3-fluorobenzyloxy)-5, 5,8, 8-tetramethyl- 5, 6, 7, 8-tetrahydro-2-naphthylselanlethynyl) benzoic acid 650 mg (1.2 mmol) of methyl 4- [4- (3-fluorobenzyloxy)- 5,5, 8,8-tetramethyl-5, 6,7, 8-tetrahydro-2- naphthylselanylethynyl] benzoate are dissolved in 20 mL of THF. 10 mL of water are added, followed by addition of 240 mg (6 mmol) of sodium hydroxide. The medium is stirred for 4 hours at 80°C and then acidified with 1 N hydrochloric acid and extracted with ethyl acetate. The residue obtained is purified by chromatography (eluent: 1/1 heptane/ethyl acetate) and then recrystallized in a heptane/ethyl acetate mixture. A pure yellow crystalline solid is obtained (m = 577 mg; yield = 90% ; m. p. = 206°C.

1H NMR (DMSO) : 1.31 (S, 6H); 1.40 (S, 6H); 1.63-1. 68 (m, 4H); 5.24 (s, 2H) ; 7. 17 (s, 1H): 7.22 (m, 1H) ; 7.32-7. 37 (m, 3H); 7.48 (m, 11H) ; 7.63 (d, J = 8. 2 Hz, 2H); 8.01 (d, J = 8.2 Hz, 2H); 13.1 (bs, 1H).

EXAMPLE 2-4- [5, 5,8, 8-tetramethyl-4- (4- methylbenzyloxy)-5, 6, 7, 8-tetrahydro-2- naphthylselanylethynyl] benzoic acid a. Methyl 4- [5, 5,8, 8-tetramethyl-4- (4- methylbenzyloxy)-5, 6, 7, 8-tetrahydro-2- naphthylselanylethynylJbenzoate In a manner similar to that of Example lf, by reacting

600 mg (1.35 mmol) of methyl 4- (4-hydroxy-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2- naphthylselanylethynyl) benzoate with 250 mg (1.8 mmol) of potassium carbonate and 274 FL (1. 5 mmol) of 4-methylbenzyl bromide. A white solid is obtained (m = 708 mg; yield = 96% ; m. p. = 154°C). b. 4- [5, 5, 8, 8-tetramethyl-4- (4-methylbenzyloxy)-.

5,6, 7, 8-tetrahydro-2-naphthylselanylethynyl] benzoic acid In a manner similar to Example lg, by reacting 650 mg (1.2 mmol) of methyl 4- [5, 5,8, 8-tetramethyl-4- (4- methylbenzyloxy) -5,6, 7,8-tetrahydro-2- naphthylselanylethynyl] benzoate with 240 mg of sodium hydroxide. A yellow crystallized solid is obtained (m = 580 mg; yield = 91% ; m. p. = 254°C).

1H NMR (CDC13+DMSO) : 1.29 (s, 6H); 1.37 (s, 6H); 1.61- 1.64 (m, 4H); 2.40 (s, 3H); 5.04 (s, 2H); 7.0 (s, 1H): 7. 16 (m, 3H); 7.17 (m, 2H); 7.45 (d, J = 6.8 Hz, 2H); 8.00 (d, J = 6. 8 Hz, 2H) EXAMPLE 3-4- [4- (4-tert-butylbenzyloxy)-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2- naphthylselanylethynylZbenzoic acid a. Methyl 4- [5, 5,8, 8-tetramethyl-4- (4-tert- butylbenzyloxy)-5, 6,7, 8-tetrahydro-2- naphthylselanylethynyl] benzoate In a manner similar to that of Example lf, by reacting 600 mg (1.38 mmol) of methyl 4- (4-hydroxy-5, 5,8, 8-

tetramethyl-5,6, 7,8-tetrahydro-2- naphthylselanylethynyl) benzoate with 240 mg (1.6 mmol) of potassium carbonate and 300 AL (1.6. mmol) of 4-tert-butylbenzyl bromide. A white solid is obtained (m = 640 mg; yield = 80% ; m. p. = 138°C). b. 4- [5, 5, 8, 8-tetramethyl-4- (4-tert-butylbenzyloxy)- 5, 6, 7, 8-tetrahydro-2-naphthylselanylethynyl] benzoic acid In a manner similar to that of Example lg, by reacting 640 mg (1.2 mmol) of methyl 4- [5, 5,8, 8-tetramethyl-4- (4-tert-butylbenzyloxy)-5, 6,7, 8-tetrahydro-2- napthylselanylethynyl] benzoate with 240 mg of sodium hydroxide. A yellow crystallized solid is obtained (m = 530 mg; yield = 92% ; m. p. = 285°C).

H NMR (CDC13) 1.24 (s, 6H) ; 1. 35 (s, 9H); 1.42 (s, 6H) ; 1.66 (m, 4H); 5.09 (s. 2H); 7.04 (d, 1H, 1. 6Hz); 7.22 (d, 1H, 1. 6Hz); 7.40 (dd, 4H, J1 = 4Hz, J2 = 13Hz) ; 7.52 (d, 2H, 8Hz); 8.06 (d, 2H, 8Hz).

EXAMPLE 4-4- [4- (3, 4-difluorobenzyloxy) -5,5, 8,8- tetramethyl-5,6, 7,8-tetrahydro-2- naphthylselanylethynyl] benzoic acid a. Methyl 4-[5, 5,8, 8-tetramethyl-4- (3, 4- difluorobenzyloxy)-5, 6, 7, 8-tetrahydro-2- naphthylselanylethynyl] benzoate In a manner similar to Example lf, by reacting 600 mg (1.38 mmol) of methyl 4- (4-hydroxy-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthylselanylethynyl] benzoate

with 240 mg (1.6 mmol) of potassium carbonate and 210 aL (1. 6. mmol) of 3,4-difluorobenzyl bromide. A white solid is obtained (m = 680 mg; yield = 86% ; m. p.

= 118°C). b. 4- [5, 5,8, 8-tetramethyl-4- (3, 4-difluorobenzyloxy)- 5, 6, 7, 8-tetrahydro-2-naphthylselanylethynyl]benzoic acid In a manner similar to that of Example 1g, by reacting 680 mg (1.2 mmol) of methyl 4- [5, 5,8, 8-tetramethyl-4- (3,4-difluorobenzyloxy)-5, 6,7, 8-tetrahydro-2- naphthylselanylethynyl] benzoate with 240 mg of sodium hydroxide. A yellow crystallized solid is obtained (m = 402 mg; yield = 61% ; m. p. = 218°C).

1H NMR (CDC13) 1. 32 (s, 6H) ; 1. 39 (s, 6H); 1. 66 (m, 4H) ; 5.06 (s, 2H); 6. 94 (d, 1H, 4Hz); 7.14 (m, 2H); 7.23 (m, 1H) ; 7.28 (d, 1H, 4Hz); 7.51 (d, 2H, 5,6Hz) ; 8.07 (d, 2H, 4Hz).

EXAMPLE 5-4- [4- (2, 4-difluorobenzyloxy) -5,5, 8,8- tetramethyl-5,6, 7,8-tetrahydro-2- naphthylselanylethynyl] benzoic acid a. Methyl 4- (5, 5, 8, 8-tetramethyl-4- (2, 4- difluorobenzyloxy)-5, 6, 7, 8-tetrahydro-2- naphthylselanylethynylJbenzoic acid In a manner similar to that of Example lf, by reacting 600 mg (1.38 mmol) of methyl 4- (4-hydroxy-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2- naphthylselanylethynyl] benzoic acid with 240 mg

(1.6 mmol) of potassium carbonate and 200 FL (1.7 mmol) of 2,4-difluorobenzyl bromide. A white solid is obtained (m = 790 mg; yield = 100% ; m. p. = 115°C). b. 4-5, 5,8, 8-tetramethyl-4-(2,4-difluorobenzyloxy)- 5, 6, 7, 8-tetrahydro-2-naphthylselanylethynyl] benzoic acid In a manner similar to that of Example lg, by reacting 790 mg (1.4 mmol) of methyl 4- [5, 5,8, 8-tetramethyl-4- (2,4-difluorobenzyloxy)-5, 6,7, 8-tetrahydro-2- naphthylselanylethynyl] benzoate with 240 mg of sodium hydroxide. A yellow crystallized solid is obtained (m = 502 mg; yield = 65% ; m. p. = 219°C).

1H NMR (CDC13) 1.31 (s, 6H) ; 1. 37 (s, 6H); 1.65 (m, 4H) ; 5.12 (s, 2H); 6.90 (m, 2H); 7.03 (d, 1H, 1. 6Hz); 7.22 (d, 1H, 2Hz); 7.51 (m, 3H); 8.08 (d, 2H, 8Hz).

EXAMPLE 6-4- (4- (4-trifluoromethylbenzyloxy)- (5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2- naphthylselanylethynyl] benzoic acid a. Methyl 4- [5, 5,8, 8-tetramethyl-4- (4- trifluoromethylbenzyloxy)-5, 6, 7, 8-tetrahydro-2- naphthylselanylethynyl) benzoate In a manner similar to that of Example lf, by reacting 590 mg (1.3 mmol) of methyl 4- (4-hydroxy-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2- naphthylselanylethynyl] benzoate with 240 mg (1. 6 mmol) of potassium carbonate and 383 mg (1.6 mmol) of 4-trifluoromethylbenzyl bromide. A white solid is

obtained (m = 840 mg; yield = 100% ; m. p. = 156°C). b. 4-f5, 5, 8, 8-tetramethyl-4-(4- trifluoromethylbenzyloxy)-5, 6,7, 8-tetrahydro-2- naphthylselanylethynyl) benzoic acid In a manner similar to that of Example lg, by reacting 840 mg (1.4 mmol) of methyl 4- [5, 5,8, 8-tetramethyl-4- (4-trifluoromethylbenzyloxy) -5,6, 7,8-tetrahydro-2- naphthylselanylethynyl] benzoate with 240 mg of sodium hydroxide. A white crystallized solid is obtained (m = 614 mg; yield = 72% ; m. p. = 253°C).

1H NMR (DMSO) 1.17 (s, 6H); 1.34 (s, 6H); 1.59 (m, 4H); 5.27 (s, 2H); 7.11 (d, 1H, 4Hz); 7.27 (d, 1H, 4Hz); 7.55 (d, 2H, 8Hz); 7.67 (d, 2H, 8Hz); 7.73 (d, 2H, 8Hz); 7.94 (d, 2H, 8Hz); 13.10 (s, 1H).

EXAMPLE 7-4- [5, 5,8, 8-tetramethyl-4- (naphthylmethoxy)- 5,6, 7, 8-tetrahydro-2-naphthylselanylethynyl] benzoic acid a. Methyl 4- [5, 5,8, 8-tetramethyl-4- (naphthylmethoxy)- 5,6, 7, 8-tetrahydro-2-naphthylselanylethynyl] benzoate In a manner similar to that of Example lf, by reacting 368 mg (0.8 mmol) of methyl 4- (4-hydroxy-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2- naphthylselanylethynyl) benzoate with 140 mg (1 mmol) of potassium carbonate and 221 mg (1 mmol) of 2-bromomethylnaphthalene. A white solid is obtained (m = 400 mg; yield = 83% ; m. p. = 134°C). b. 4- [5, 5,8, 8-tetramethyl-4- (naphthylmethoxy)-

5, 6, 7, 8-tetrahydro-2-naphthylselanylethynyl] benzoic acid In a manner similar to that of Example lg, by reacting 400 mg (0.7 mmol) of methyl 4- [5, 5,8, 8-tetramethyl-4- (naphthylmethoxy) -5,6, 7,8-tetrahydro-2- naphthylselanylethynyl] benzoate with 140 mg of sodium hydroxide. A white crystallized solid is obtained (m = 258 mg; yield = 65% ; m. p. = 254°C).

1H NMR (DMSO) 1.25 (s, 6H); 1.35 (s, 6H); 1.58 (m, 4H); 5.31 (s, 2H); 7. 19 (d, 1H, 1. 6Hz); 7.26 (d, 1H, 1. 6Hz); 7.53 (m, 4H); 7.59 (d, 1H, 8Hz); 7. 85 (m, 1H); 7.96 (m, 4H); 7.98 (s, 1H).

EXAMPLE 8-4- [4- (4-chlorobenzyloxy)-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2- naphthylselanylethynyl] benzoic acid a. Methyl 4-f5, 5, 8, 8-tetramethyl-4- (4- chlorobenzyloxy)-5, 6, 7, 8-tetrahydro-2- naphthylselanylethynylJbenzoate In a manner similar to that of Example lf, by reacting 370 mg (0. 8 mmol) of methyl 4- (4-hydroxy-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2- naphthylselanylethynyl] benzoate with 140 mg (1 mmol) of potassium carbonate and 205 mg (1 mmol) of 4-chlorobenzyl bromide. A white solid is obtained (m = 300 mg; yield = 64%). b. 4- [5, 5, 8, 8-tetramethyl-4- (4-chlorobenzyloxy)- 5,6, 7, 8-tetrahydro-2-naphthylselanylethynylJbenzoic

acid In a manner similar to that of Example lg, by reacting 300 mg (0. 5 mmol) of methyl 4- [5, 5,8, 8-tetramethyl-4- (4-chlorobenzyloxy) -5,6, 7, 8-tetrahydro-2- naphthylselanylethynyl] benzoate with 110 mg of sodium hydroxide. A white crystallized solid is obtained (m = 210 mg; yield = 72%, m. p. = 255°C).

1H NMR (DMSO) 1.24 (s, 6H); 1.32 (s, 6H); 1.59 (m, 4H); 5.15 (s, 2H); 7.10 (s, 1H); 7.26 (s, 1H) ; 7.43 (d, 2H, 8Hz); 7.48 (d, 2H, 8Hz); 7.56 (d, 2H, 8Hz); 7.95 (d, 2H, 8Hz); 13.10 (s, 1H).

EXAMPLE 9-4- [4- (4-bromobenzyloxy)-5, 5, 8, 8- tetramethyl-5, 6,7, 8, -tetrahydro-2- naphthylselanylethynyl] benzoic acid a. Methyl 4- [5, 5,8, 8-tetramethyl-4-(4- bromobenzyloxy)-5, 6,7, 8-tetrahydro-2- naphthylselanylethynyl] benzoate In a manner similar to that of Example lf, by reacting 215 mg (0.5 mmol) of methyl 4- (4-hydroxy-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2- naphthylselanylethynyl] benzoate with 80 mg (0.6 mmol) of potassium carbonate and 146 mg (0.6 mmol) of 4-bromobenzyl bromide. A white solid is obtained (m = 320 mg; yield = 100%). b. 4- [5, 5,8, 8-tetramethyl-4- (4-bromobenzyloxy)- 5,6, 7, 8-tetrahydro-2-naphthylselanylethynyl] benzoic acid

In a manner similar to that of Example lg, by reacting 320 mg (0.5 mmol) of methyl 4- [5, 5,8, 8-tetramethyl-4- (4-bromobenzyloxy) -5,6, 7,8-tetrahydro-2- naphthylselanylethynyl] benzoate with 110 mg of sodium hydroxide. A white crystallized solid is obtained (m = 240 mg; yield = 66% ; m. p. = 265°C).

1H NMR (DMSO) 1.24 (s, 6H); 1.32 (s, 6H); 1.59 (m, 4H); 5.13 (s, 2H); 7.09 (d, 1H, 1. 2Hz); 7.25 (d, 1H, 1. 2Hz); 7.41 (d, 2H, 8.4Hz) ; 7.56 (d, 4H, 7.2Hz) ; 7.95 (d, 2H, 8Hz); 13. 10 (s, 1H).

EXAMPLE 10-4- [5, 5,8, 8-tetramethyl-4- (3- methylbenzyloxy) -5,6, 7,8-tetrahydro-2- naphthylselanylethynyl] benzoic acid a. Methyl 4-/'5, 5,8, 8-tetramethyl-4-(3- methylbenzyloxy)-5, 6,7, 8-tetrahydro-2- naphthylselanylethynyl] benzoate In a manner similar to that of Example lf, by reacting 600 mg (1.35 mmol) of methyl 4- (4-hydroxy-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2- naphthylselanylethynyl] benzoate with 250 mg (1.8 mmol) of potassium carbonate and 274 FL (1.5 mmol) of 3-methylbenzyl bromide. A white solid is obtained (m = 708 mg; yield 96% ; m. p. = 102°C). b. 4- [5, 5,8, 8-tetramethyl-4- (3-methylbenzyloxy)- 5,6, 7, 8-tetrahydro-2-naphthylselanylethynyl]benzoic acid In a similar manner to that of Example lg, by reacting

650 mg (1.2 mmol) of methyl 4- [5, 5,8, 8-tetramethyl-4- (3-methylbenzyloxy)-5, 6,7, 8-tetrahydro-2- naphthylselanylethynyl] benzoate with 240 mg of sodium hydroxide. A yellow crystallized solid is obtained (m = 600 mg; yield = 94% ; m. p. 225°C).

1H NMR (DMSO) : 1.29 (s, 6H); 1.38 (s, 6H): 1. 62-1. 65 (m, 4H); 2.34 (s, 3H); 5.15 (s, 2H); 7.16-7. 19 (m, 2H); 7.29-7. 31 (m, 4H); 7.63 (d, J = 8.2Hz, 2H); 8.00 (d, J = 8.2Hz, 2H); 13.3 (bs, 1H).

EXAMPLE 11-4- [5, 5,8, 8-tetramethyl-4- (4- methylbenzyloxy) -5,6, 7,8-tetrahydro-2- naphthylselanylethynyl] benzoic acid a. Methyl 4-[5,5, 8, 8-tetramethyl-4- (4- fluorobenzyloxy)-5, 6,7, 8-tetrahydro-2- naphthylselanylethynyl] benzoate In a manner similar to that of Example lf, by reacting 600 mg (1.35 mmol) of methyl 4- (4-hydroxy-5,5, 8, 8- tetramethyl-5,6, 7,8-tetrahydro-2- naphthylselanylethynyl] benzoate with 250 mg (1.8 mmol) of potassium carbonate and 185 ZL (1.5 mmol) of 4-fluorobenzyl bromide. A white solid is obtained (m = 690 mg; yield = 93% ; m. p. = 121°C). b. 4- [5, 5, 8, 8-tetramethyl-4- (4-fluorobenzyloxy)- 5,6, 7, 8-tetrahydro-2-naphthylselanylethynyl] benzoic acid In a manner similar to that of Example lg, by reacting 650 mg (1.2 mmol) of methyl 4- [5, 5,8, 8-tetramethyl-4-

(4-fluorobenzyloxy)-5, 6,7, 8-tetrahydro-2- naphthylselanylethynyl] benzoate with 240 mg of sodium hydroxide. A yellow crystallized solid is obtained (m = 619 mg; yield = 98% ; m. p. = 228°C).

1H NMR (DMSO) : 1.14 (s, 6H); 1.21 (s, 6H); 1.45-1. 49 (m, 4H); 5.02 (s, 2H); 7.02 (s, 1H); 7. 08-7. 15 (m, 3H); 7.39-7. 42 (m, 2H); 7.47 (d, J = 8. 1Hz, 2H); 7.85 (d, J = 8. 1Hz, 2H); 12.9 (bs, 1H).

EXAMPLE 12-4- (4-hydroxy-3- [5, 5,8, 8-tetramethyl-4- (4- trifluoromethylbenzyloxy) -5,6, 7,8-tetrahydro-2- naphthyl] prop-l-ynyl} benzoic acid a. 4-hydroxy-5, 5,8, 8-tetramethyl-5, 6, 7, 8-tetrahydro- 2-naphthalenecarbaldehyde 30 g (106 mmol) of 3-bromo-5,5, 8,8-tetramethyl-5, 6,7, 8- tetrahydro-1-naphthyl (Example 5a) are dissolved in 500 mL of anhydrous THF. The medium is cooled to-78°C, and 156 mL (265 mmol) of tert-butyllithium are then added dropwise. After 45 minutes at this temperature, 12.3 mL (159 mmol) of dimethylformamide are added. The mixture is warmed to room temperature and then treated with 1 N hydrochloric acid solution and extracted with ethyl acetate. The residue obtained is then purified by chromatography (eluent: 9/1 heptane/ethyl acetate). A white solid is obtained (m = 16. 5g ; yield = 67% ; m. p. = 144°C). b. 5,5, 8, 8-tetramethyl-4- (4- trifluoromethylbenzyloxy)-5, 6, 7, 8-tetrahydro-2-

naphthalenecarbaldehyde In a manner similar to that of Example lc, by reacting 700 mg (3 mmol) of 4-hydroxy-5,5, 8,8-tetramethyl- 5,6, 7,8-tetrahydro-2-naphthalenecarbaldehyde with 160 mg of sodium hydride and 789 mg (3.3 mmol) of 4- trifluoromethylbenzyl bromide. A yellow oil is obtained (m = 1.15 g; yield = 100%). c. 1- [5, 5,8, 8-tetramethyl-4- (4- <BR> <BR> trifluoromethylbenzyloxy)-5, 6, 7, 8-tetrahydro-2-<BR> <BR> naphthyl) prop-2-yn-2-o1 In a manner similar to that of Example lf, by reacting 1.15 g (3 mmol) of 5,5, 8, 8-tetramethyl-4- (4- trifluoromethylbenzyloxy) -5,6, 7,8-tetrahydro-2- naphthalenecarbaldehyde with 7.7 mL (7.7 mmol) of 1 N ethynylmagnesium bromide solution. A colourless oil is obtained (m = 1.2 g; yield = 100%). d. 4-{3-hydroxy-3-[5, 5,8, 8-tetramethyl-4- (4- trifluoromethylbenzyloxy)-5, 6, 7, 8-tetrahydro-2- naphthyl]prop-1-ynyl}benzoic acid In a manner similar to that of Example lg, by reacting 1.2 g (2.8 mmol) of 1- [5, 5,8, 8-tetramethyl-4- (4- trifluoromethylbenzyloxy) -5,6, 7,8-tetrahydro-2- naphthyl] prop-2-yn-1-ol with 600 mg (2.4 mmol) of 4- iodobenzoic acid in the presence of 23 mg of copper iodide and 42 mg of bis (triphenylphosphine) dichloro- palladium. The desired product is obtained in the form of orange-coloured crystals (m = 930 mg; yield = 72%,

m. p. 222°C).

1H NMR (DMSO) 1.25 (s, 6H); 1.37 (s, 6H) ; 1.60 (m, 4H); 5.25 (s, 2H) ; 5.52 (s, 2H) ; 6.10 (d, 1H) ; 6.99 (s, 1H) ; 7.15 (s, 1H) ; 7.49 (d, 2H, 8Hz); 7.73 (dd, 4H, 8Hz, 12Hz) ; 7.92 (d, 2H, 8Hz); 13.1 (s, 1H).

EXAMPLE 13 - 4-{3-hydroxy-3- [5,5, 8,8-tetramethyl-4- (4- methylbenzyloxy) -5, 6, 7,8-tetrahydro-2-naphthyl]prop-1- ynylAbenzoic acid a. 5,5, 8, 8-tetramethyl-4- (4-methylbenzyloxy)-5, 6,7, 8- tetrahydro-2-naphthalenecarbaldehyde In a manner similar to that of Example 1c, by reacting 700 mg (3 mmol) of 4-hydroxy-5,5, 8,8-tetramethyl- 5,6, 7,8-tetrahydro-2-naphthalenecarbaldehyde with 160 mg of sodium hydride and 611 mg (3.3 mmol) of 4- methylbenzyl bromide. A colourless oil is obtained (m = 1.12 g; yield = 100%). b. 1- [5, 5,8, 8-tetramethyl-4- (4-methylbenzyloxy)- 5,6, 7, 8-tetrahydro-2-naphthyl] prop-2-yn-l-ol In a manner similar to that of Example lf, by reacting 1.12 g (3.3 mmol) of 5,5, 8, 8-tetramethyl-4- (4- methylbenzyloxy) -5,6, 7,8-tetrahydro-2- naphthalenecarbaldehyde with 8.7 mL (8.7 mmol) of 1 N ethynylmagnesium bromide solution. A colourless oil is obtained (m = 1.22 g; yield = 100%). c. 4-f3-hydroxy-3- [5, 5,8, 8-tetramethyl-4- (4- methylbenzyloxy)-5, 6, 7, 8-tetrahydro-2-naphthyl] prop-1- ynyl} benzoic acid

In a manner similar to that of Example lg, by reacting 1.22 g (3.3 mmol) of 1- [5, 5,8, 8-tetramethyl-4- (4- methylbenzyloxy) -5,6, 7, 8-tetrahydro-2-naphthyl] prop-2- yn-l-ol with 680 mg (2.8 mmol) of 4-iodobenzoic acid in the presence of 27 mg of copper iodide and 49 mg of bis (triphenylphosphine) dichloropalladium, The desired product is obtained in the form of beige-coloured crystals (m = 900 mg; yield = 67% ; m. p. = 219°C).

1H NMR (DMSO) 1.24 (s, 6H); 1.33 (s, 6H); 1.59 (m, 4H); 2.29 (s, 3H); 5.06 (s, 2H); 5.52 (d, 1H, 4.8Hz) ; 6.10 (d, 1H, 5.6Hz) ; 7.01 (d, 1H, 1. 2Hz); 7.12 (d, 1H, 0.8Hz) ; 7.18 (d, 2H, 7.6Hz) ; 7. 37 (d, 2H, 8Hz); 7. 51 (d, 2H, 8Hz); 7.93 (d, 2H, 8Hz); 13.1 (s, 1H).

EXAMPLE 14-4- 3- [4- (4-tert-butylbenzyloxy)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxy- prop-l-ynyl) benzoic acid a. 4- (4-tert-butylbenzyloxy)-5, 5,8, 8-tetramethyl- 5, 6, 7, 8-tetrahydro-2-naphthalenecarbaldehyde In a manner similar to that of Example lc, by reacting 700 mg (3 mmol) of 4-hydroxy-5,5, 8,8-tetramethyl- 5,6, 7,8-tetrahydro-2-naphthalenecarbaldehyde with 160 mg of sodium hydride and 600 gL (3.3 mmol) of 4-tert-butylbenzyl bromide. A colourless oil is obtained (m = 1.2 g; yield = 100%). b. 1- [4- (4-tert-butylbenzyloxy)-5, 5,8, 8-tetramethyl- 5, 6, 7, 8-tetrahydro-2-naphthyl] prop-2-yn-1-ol In a similar manner to that of Example lf, by reacting

1.2 g (3 mmol) of 4- (4-tert-butylbenzyloxy)-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2- naphthalenecarbaldehyde with 7.8 mL (7.8 mmol) of 1 N ethynylmagnesium bromide solution. A colourless oil is obtained (m = 760 mg; yield = 63%). <BR> <BR> <BR> <BR> <BR> <BR> c. 4- (3- (4- (4-tert-butylbenzyloxy)-5, 5, 8, 8-<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> tetramethyl-5, 6, 7, 8-tetrahydro-2-naphthyl J-3-hydroxy- prop-1-ynylbenzoic acid In a manner similar to that of Example lg, by reacting 760 mg (1.9 mmol) of 1- [4- (4-tert-butylbenzyloxy)- 5,5, 8,8-tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl] prop- 2-yn-1-o1 with 390 mg (1.6 mmol) of 4-iodobenzoic acid in the presence of 15 mg of copper iodide and 28 mg of bis (triphenylphosphine) dichloropalladium. The desired product is obtained in the form of white crystals (m = 600 mg ; yield = 71% ; m. p. = 254°C).

H NMR (DMSO) 1.25 (s, 6H); 1.26 (s, 9H): 1.36 (s, 6H): 1.59 (m, 4H): 5.09 (s, 2H); 5,53 (d, 1H, 5.6Hz) ; 6.10 (d, 1H, 6.4Hz) ; 7.05 (s, 1H): 7.13 (s, 1H); 7.39 (dd, 4H, 8Hz, 16Hz) ; 7.53 (d, 2H, 8.4Hz) ; 7.93 (d, 2H, 8.4Hz) ; 13.10 (s, 1H).

EXAMPLE 15 -4 4-{3-[4-(4-fluorobenzyloxy)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3-hydroxy- prop-l-ynyl} benzoic acid a. 4- (4-fluorobenzyloxy)-5, 5,8, 8-tetramethyl-5, 6, 7,8- tetrahydro-2-naphthalenecarbaldehyde In a manner similar to that of Example lc, by reacting

700 mg (3 mmol) of 4-hydroxy-5,5, 8,8-tetramethyl- 5,6, 7,8-tetrahydro-2-naphthalenecarbaldehyde with 160 mg of sodium hydride and 410 ßL (3.3 mmol) of 4- fluorobenzyl bromide. A colourless oil is obtained (m = 1.2 g; yield = 100%). b. 1- (4- (4-fluorobenzyloxy)-5, 5, 8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl] prop-2-yn-1-ol In a manner similar to that of Example If, by reacting 1.0 g (2.9 mmol) of 4- (4-fluorobenzyloxy-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2- naphthalenecarbaldehyde with 4.5 mL (4.5 mmol) of 1 N ethynylmagnesium bromide solution. A colourless oil is obtained (m = 580 mg; yield = 55%). c. 4- (. 3-fg- 4-fluorobenzyloxy)-5, 5, 8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl)-3-hydroxy-prop-1- ynyl} benzoic acid In a manner similar to that of Example lg, by reacting 580 mg (1.6 mmol) of 1-[4-(4-fluorobenzyloxy)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl] prop-2-yn-1- ol with 330 mg (1.3 mmol) of 4-iodobenzoic acid in the presence of 12 mg of copper iodide and 23 mg of bis (triphenylphosphine) dichloropalladium. The desired product is obtained in the form of beige-coloured crystals (m = 420 mg; yield = 67% ; m. p. 188°C).

1H NMR (DMSO) 1.24 (s, 6H); 1.59 (s, 6H); 5.10 (s, 2H); 5.52 (d, 1H, 4.3Hz) ; 6.10 (s, 1H); 7.00 (d, 1H, 1. 2Hz); 7.13 (d, 1H, 1. 2Hz), 7.19 (t, 2H, 8.8Hz) ; 7.50 (m. 4H);

7.92 (d, 2H, 8.4Hz).

EXAMPLE 16-4-{(E)-3-t4-(4-fluorobenzyloxy)-5, 5,8, 8- tetramethyl-5,6, 7, 8-tetrahydro-2-naphthyl]-3- oxopropenyl} benzoic acid a. 1- (4-hydroxy-5, 5, 8, 8-tetramethyl-5, 6, 7, 8- tetrahydro-2-naphthyl) ethanone 5 g (22 mmol) of 4-hydroxy-5,5, 8,8-tetramethyl-5, 6,7, 8- tetrahydro-2-naphthalenecarbaldehyde (Example 16a) are dissolved in 150 mL of THF. The medium is cooled to 0°C and 15 mL (45 mmol) of 3M methylmagnesium bromide solution are then added. After 30 minutes, the medium is treated with saturated ammonium chloride solution and then extracted with ethyl acetate. The residue obtained is dissolved in 40 mL of dichloromethane. A solution of 6.5 mL of DMSO (84 mmol) in 50 mL of dichloromethane is then added slowly to a solution, prepared beforehand, of 3.75 mL (43 mmol) of oxalyl chloride in 100 mL of dichloromethane at-78°C. The solution containing the product obtained previously is then added to this reaction medium very slowly, followed by addition of 23 mL (165 mmol) of triethylamine. The reaction medium is warmed slowly to room temperature and is then treated with saturated ammonium chloride solution and extracted with dichloromethane. The residue is purified by chromatography (eluent : 9/1 heptane/ethyl acetate). A thick yellow oil is obtained (m = 2.6 g; yield = 51%).

b. Methyl 4- [ (E)-3- (4-hydroxy-5, 5, 8, 8-tetramethyl- 5, 6, 7, 8-tetrahydro-2-naphthyl)-3-oxopropenylJbenzoate 1.4 g (4.9 mmol) of 1- (4-hydroxy-5, 5,8, 8-tetramethyl- 5,6, 7,8-tetrahydro-2-naphthyl) ethanone are dissolved in 50 mL of methanol. 660 mg (4.4 mmol) of 4- carboxybenzaldehyde and 2.3 mL (20 mmol) of 47% KOH solution are then added. The reaction medium is stirred at 65°C for 48 hours, and then cooled and acidified, and finally extracted with ethyl acetate. The residue obtained is then dissolved in 50 mL of methanol and 1 mL of concentrated sulphuric acid. The reaction medium is stirred at reflux for 12 hours and then cooled, hydrolyzed, and extracted with dichloromethane.

The residue obtained is purified by chromatography (eluent: 85/15 heptane/ethyl acetate). A yellow crystallized solid is obtained (m = 390 mg; yield = 20%). c. Methyl 4- [ ( (E)-3- [4- (4-fluorobenz_Vloxy-5, 5,8, 8- tetramethyl-5, 6, 7, 8-tetrahydro-2-naphthylJ-3- oxopropenyl} benzoate In a manner similar to Example lf, by reacting 340 mg (0.85 mmol) of methyl 4-[(E)-3-(4-hydroxy-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl)-3- oxopropenyl] benzoate with 140 mg (1 mmol) of potassium carbonate and 120 AL (1 mmol) of 4-fluorobenzyl bromide. The product is obtained in the form of yellow crystals (m = 320 mg; yield = 75% ; m. p. = 142°C).

d. 4-{(E)-3-[4-(4-fluorobenzyloxy)-5, 5, 8, 8- tetramethyl-5, 6, 7, 8-tetrahydro-2-naphthyl]-3- oxopropenyl}benzoic acid In a manner similar to that of Example lg, by reacting 320 mg (0.6 mmol) of methyl 4- { (E)-3- [4- (4- fluorobenzyloxy) -5,5, 8,8-tetramethyl-5, 6,7, 8- tetrahydro-2-naphthyl]-3-oxopropenyl} benzoate with 128 mg (3 mmol) of sodium hydroxide. The desired product is obtained in the form of a white crystallized solid (m = 170 mg; yield = 55% ; m. p. = 241°C).

1H NMR (DMSO) 1.33 (S, 6H); 1.35 (s, 6H); 1.63 (m, 4H); 5.22 (s, 2H); 7.27 (t, 2H, 8Hz); 7.52 (s, 1H); 7.58 (dd, 2H, 8Hz, 2.4Hz) ; 7.78 (s, 2H); 8.01 (s, 4H).

EXAMPLE 17-6- (1- 4- (4-fluorobenzyloxy)-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2- naphthyl) methanoyl} naphthalene-2-carboxylic acid a. 4-ethoxymethoxy-5, 5,8, 8-tetramethyl-5, 6, 7,8- tetrahydro-2-naphthalene boronic acid 8.9 g (26 mmol) of 7-bromo-5-ethoxymethoxy-1, 1, 4,4- tetramethyl-1, 2,3, 4-tetrahydronaphthalene (Examle 5b) are dissolved in 200 mL of anhydrous THF and the mixture is cooled to-78°C. 12.5 mL (31 mmol) of 2.5M butyllithium solution are added and the mixture is stirred for 1 hour. 7.2 mL (31 mmol) of triisopropyl borate are then added and the reaction medium is stirred at this temperature for 1 hour, then warmed to room temperature and treated with saturated ammonium

chloride solution. The residue obtained after extraction is washed with heptane. A white powder is obtained (m = 6.8 g; yield = 85%). b. Methyl 6- (1- (4-ethoxymethoxy-5, 5,8, 8-tetramethyl- 5, 6, 7, 8-tetrahydro-2-naphthyl) methanoyl]-2- naphthalenecarboxylate.

5 g (16 mmol) of 4-ethoxymethoxy-5,5, 8,8-tetramethyl- 5,6, 7,8-tetrahydro-2-naphthalene boronic acid are dissolved in 100 mL of toluene. 26 g (80 mmol) of caesium carbonate are added and the medium is degassed for 15 minutes with a flow of nitrogen. 14 mg (0.8 mmol) of palladium chloride are added, followed by 5.47 g (22 mmol) of methyl 6-chlorocarbonyl-2- naphthalenecarboxylate in 1 g portions. The reaction medium is refluxed for 15 hours and then hydrolysed and extracted with ethyl acetate. The residue obtained is purified by chromatography (eluent: 9/1 heptane/ethyl acetate). The product is then recrystallized from an ethyl acetate/heptane mixture (m = 4.3 g; yield = 59% ; m. p. = 96°C). c. Methyl 6- [1- (4-hydroxy-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl)methanoyl]-2- naphthalenecarboxylate 3.5 g (7.6 mmol) of methyl 6- [l- (4-ethoxymethoxy- 5,5, 8,8-tetramethyl-5, 6,7, 8-tetrahydro-2- naphthyl) methanoyl]-2- naphthalenecarboxylate are dissolved in 50 mL. of THF and 100 mL of methanol. 1 mL

of concentrated sulphuric acid is added and the reaction medium is heated at 80°C for 2 hours and then cooled and hydrolyzed. A white solid is obtained (m = 2.6 g; yield = 84% ; m. p. = 222°C). d. Methyl 6- (1- 4- (4-fluorobenzyloxy)-5, 5,8, 8- tetramethyl-5,6, 7, 8-t : et : rahydro-2-naph. thyllmet : hanoyll-2- naphthalenecarboxylate In a manner similar to that of Example lf, by reacting 1.5 g (3.6 mmol) of methyl 6- [l- (4-hydroxy-5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2-naphthyl) methanoyl]-2- naphthalenecarboxylate with 600 mg (4.5 mmol) of potassium carbonate and 540 gL (4.3 mmol) of 4- fluorobenzyl bromide. The product is obtained in the form of white crystals (m = 320 mg; yield 98% ; mp. = 179°C). e. 6-f1-[4- (4-fluorobenzyloxy)-5, 5,8, 8-tetramethyl- 5,6, 7, 8-tetrahydro-2-naphthyl]methanoyl}-2- naphthalenecarboxylic acid In a manner similar to that of Example lg, by reacting 250 mg (0.5 mmol) of methyl 6- {1- [4- (4- fluorobenzyloxy) -5,5, 8,8-tetramethyl-5, 6,7, 8- tetrahydro-2-naphthyl] methanoyl}-2- naphthalenecarboxylate with 40 mg of sodium hydroxide.

A white crystallized solid is obtained (m = 235 mg; yield = 66% ; m. p. = 277°C).

1H NMR (DMSO) 1.24 (s, 6H); 1.39 (s, 6H); 1.63-1. 66 (m, 4H); 5.15 (s, 2H); 7.20-7. 27 (m, 3H); 7.41 (s, 1H):

7.49-7. 52 (m, 2H), 7.89 (d, J = 8.5Hz, 1H); 8.06 (d, J = 8. 5Hz, 1H); 8.19 (d, J = 8.7Hz, 1H) ; 8.26 (d, J = 8.6Hz, 1H); 8.37 (s, 1H); 8.70 (s, 1H).

EXAMPLE 18-6- {l- [4- (4-fluorobenzyloxy)-5, 5, 8, 8- tetramethyl-5, 6, 7, 8-tetrahydro-2-naphthyl]-1- hydroxymethyl}-2-naphthalenecarboxylic acid 245 mg (0.5 mmol) of 6- {l- [4- (4-fluorobenzyloxy)- 5,5, 8,8-tetramethyl-5, 6,7, 8-tetrahydro-2- naphthyl] methanoyl}-2-naphthalenecarboxylate are dissolved in 5 mL of THF and 5 mL of methanol, and 28 mg (0.7 mmol) of sodium borohydride are added. The medium is stirred for 1 hour, and then treated with saturated ammonium chloride solution. The residue obtained after extraction is purified by chromatography: a white solid is obtained (m = 220 mg; yield = 89% ; m. p. = 212°C).

1H NMR (DMSO) : 1.20 (s, 6H) ; 1.27 (s, 6H); 1.53-1. 55 (m, 4H); 5.01 (s, 2H); 5.79 (s, 1H); 5.98 (bs, 1H); 6.89 (s, 1H); 7.09-7. 17 (m, 3H); 7.44-7. 48 (m, 2H); 7.56 (d, J = 8.6Hz, 1H); 7.94-8. 02 (m, 4H); 8.53 (s, 1H).

EXAMPLE 19: TRANSACTIVATION TEST The activation of receptors with an agonist (activator) in HeLa cells leads to the expression of a reporter gene, luciferase, which, in the presence of a substrate, generates light. The activation of the receptors may thus be measured by quantifying the

luminescence produced after incubating the cells in the presence of a reference agonist. The inhibitory products displace the agonist from its site, thus preventing activation of the receptor. The activity is measured by quantifying the reduction in light produced. This measurement makes it possible to determine the inhibitory activity of the compounds according to the invention.

Determination of the Kdapp: In this study, a constant is determined which represents the affinity of the molecule for the receptor. Since this value can fluctuate depending on the basal activity and the expression of the receptor, it is referred to as the Kdapparent (KdApp).

To determine this constant, "crossed curves" of the test product against a reference agonist, 4- [2- (5,5, 8,8-tetramethyl-5, 6,7, 8-tetrahydro-2- naphthyl) propenyl] benzoic acid, are performed in 96- well plates. The test product is used at 10 concentrations and the reference agonist at 7 concentrations. In each well, the cells are in contact with a concentration of the test product and a concentration of the reference agonist, 4- [2- (5, 5,8, 8- tetramethyl-5,6, 7,8-tetrahydro-2- naphthyl) propenyl] benzoic acid. Measurements are also taken for the total agonist (4- [2- (5, 5,8, 8-tetramethyl-

5,6, 7, 8-tetrahydro-2-naphthyl) propenyl] benzoic acid) and inverse agonist, 4- ( (E)-3- [4- (4-tert-butylphenyl)- 5,5, 8,8-tetramethyl-5, 6,7, 8-tetrahydro-2-naphthyl]-3- oxopropenyl} benzoic acid, controls.

These crossed curves make it possible to determine the AC50 values (concentration at which 50% activation is observed) for the reference ligand at various concentrations of test product. These AC50 values are used to calculate the Schild regression by plotting a straight line corresponding to the Schild equation ("quantitation in receptor pharmacology"Terry P. Kenakin, Receptors and Channels, 2001, 7, 371-385).

In the case of an antagonist, an IC50 value (concentration that inhibits 50% of the activity) is calculated by plotting the curve of the product at the concentration of the reference ligand that gives 80% activation.

The HeLa cell lines used are stable transfectants containing the plasmids ERE-pGlob-Luc-SV- Neo (reporter gene) and RAR (a, P, y) ER-DBD-puro. These cells are inoculated into 96-well plates at a rate of 10 000 cells per well in 100 1 of DMEM medium without phenol red, and supplemented with 10% defatted calf serum. The plates are then incubated at 37°C and 7% COs for 4 hours.

The various dilutions of the test products, of the reference ligand (4- [2- (5, 5,8, 8-tetramethyl-

5,6, 7,8-tetrahydro-2-naphthyl) propenyl] benzoic acid), of the 100% control (100 nM 4- [2- (5, 5,8, 8-tetramethyl- 5,6, 7,8-tetrahydro-2-naphthyl) propenyl] benzoic acid) and of the 0% control (500 nM 4-{(E)-3-[4-(4-tert- butylphenyl) -5,5, 8, 8-tetramethyl-5, 6,7, 8-tetrahydro-2- naphthyl]-3-oxopropenyl} benzoic acid) are added at a rate of 5 Zl per well. The plates are then incubated for 18 hours at 37°C and 7% CO2.

The culture medium is removed by turning over and 100 pl of a 1: 1 PBS/luciferine mixture is added to each well. After 5 minutes, the plates are read using the luminescence detector. beta 0 RAR Kdapp ICso Kdapp IC50 Kdapp ICso (nM) (nM) (nM) (nM) (nM) (nM) Ex 1 8 14 4 6. 5 2 5 Ex 3 15 26. 25 30 48 4 10 Ex 4 2 3. 5 4 6. 4 1 2. 5 Ex 5 2 3. 5 1 1. 6 1 2. 5 Ex 10 30 52. 5 15 24 4 10 Ex 11 8 14 4 6. 4 1 2. 5

The results obtained with the compounds according to the invention clearly show Kdapp values < 100 nM and an IC50 value < 100 nM for at least one of the receptor subtypes, this clearly demonstrating a reduction in the signal, and in the luminescence in the

presence of the reference agonist. The compounds according to the invention are thus clearly inhibitors of retinoic acid receptors (RAR).

EXAMPLE 20: FORMULATION EXAMPLES This example illustrates various concrete formulations based on the compounds according to the invention.

A-ENTERAL ROUTE (a) 0.2 g tablet - Compound of Example 16 0. 001 g - Starch 0.114 g - Dicalcium phosphate 0.020 g - Silica 0.020 g Lactose 0.030 g - Talc 0.010 g - Magnesium stearate 0.005 g (b) Drinkable suspension in 5 ml ampules - Compound of Example 17 0.001 g - Glycerol 0.500 g - 70% sorbitol 0.500 g - Sodium saccharinate 0.010 g - Methyl para-hydroxybenzoate 0.040 g - Flavouring qs - Purified water qs 5 ml

(c) 0.8 g tablet Compound of Example 9 0.500 g - Pregelatinized starch 0.100 g Microcrystalline cellulose 0.115 g Lactose 0.075 g Magnesium stearate 0.010 g (d) Drinkable suspension in 10 ml ampules Compound of Example 2 0.200 g - Glycerol 1.000 g 70% sorbitol 1.000 g Sodium saccharinate 0.010 g Methyl para-hydroxybenzoate 0.080 g Flavouring qs Purified water qs 10 ml B-PARENTERAL ROUTE (a) Composition - Compound of Example 3 0.002 g - Ethyl oleate qs 10 g (b) Composition - Compound of Example 1 0. 05% - Polyethylene glycol 20% - 0.9% NaCl solution qs 100

(c) Composition - Compound of Example 3 2. 5% - Polyethylene glycol 400 20% - 0.9% NaCl solution qs 100 (d) Injectable cyclodextrin composition - Compound of Example 3 0.1 mg -ß-Cyclodextrin 0.10 g - Water for injection qs 10.00 g C-TOPICAL ROUTE (a) Ointment - Compound of Example 12 0.020 g - Isopropyl myristate 81.700 g - Liquid petroleum jelly fluid 9.100 g Silica ("Aerosil 200"sold by Degussa) 9.180 g (b) Ointment - Compound of Example 15 0.300 g - White petroleum jelly codex qs 100 g (c) Nonionic water-in-oil cream - Compound of Example 10 0.100 g - Mixture of emulsifying lanolin alcohols, waxes and oils ("Anhydrous Eucerin"sold by BDF) 39.900 g

Methyl para-hydroxybenzoate 0.075 g Propyl para-hydroxybenzoate 0.075 g Sterile demineralized water qs 100 g (d) Lotion Compound of Example 9 0.100 g - Polyethylene glycol (PEG 400) 69.900 g - 95% ethanol 30.000 g (e) Hydrophobic ointment Compound of Example 4 0.300 g Isopropyl myristate 36.400 g - Silicone oil ("Rhodorsil 47 V 300" sold by Rhone-Poulenc) 36.400 g Beeswax 13.600 g - Silicone oil ("Abil 300 000 cst" sold by Goldschmidt) qs 100 g (f) Nonionic oil-in-water cream Compound of Example 6 1.000 g Cetyl alcohol 4.000 g Glyceryl monostearate 2.500 g -PEG-50 stearate 2.500 g - Karite butter 9.200 g Propylene glycol 2.000 g Methyl para-hydroxybenzoate 0.075 g Propyl para-hydroxybenzoate 0.075 g Sterile demineralized water qs 100 g